Perspectives in the treatment of pancreatic adenocarcinoma
about
Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancerDocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Engineered Resistant-Starch (ERS) Diet Shapes Colon Microbiota Profile in Parallel with the Retardation of Tumor Growth in In Vitro and In Vivo Pancreatic Cancer ModelsInflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple OpponentsCD90 and CD24 Co-Expression Is Associated with Pancreatic Intraepithelial NeoplasiasExtended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101.ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth.Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic CancerPharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression.BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells.Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes.Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity.FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy.Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma.Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.Nanotechnologies in Pancreatic Cancer Therapy.Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.Implication of exercise interventions on sleep disturbance in patients with pancreatic cancer: a study protocol for a randomised controlled trial.Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial.The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.Photodynamic diagnosis of peritoneal metastasis in human pancreatic cancer using 5-aminolevulinic acid during staging laparoscopy.A novel prognostic marker and immunogenic membrane antigen: prohibitin (PHB) in pancreatic cancer
P2860
Q26764921-29958D9A-210A-42AA-9A5C-BAB6B549BA26Q30315797-26663420-309D-4A6A-ACBF-FEC36B0DDCA4Q33616599-9F417F1B-9EBD-442E-8D26-51E7EE9807F5Q33704284-8E9416CB-AB8E-416E-AE38-3D5A2D4E6F81Q36058936-72FD7B20-51EE-4DE1-B82D-CBEB984F3BC0Q36515365-9356402C-7D45-4E4F-8A15-D0347ADB6EECQ37618014-D457C544-CCA0-4083-A993-3BE772CB8BA0Q37742975-04499D7D-2DDE-4100-97CA-4DD98FC6EAC4Q38744237-3BA05407-FF56-4310-8FE2-C3068BA74F46Q39204274-8FB61A09-E683-4DF4-A351-8CE90CCDF975Q40510647-1FC3EF27-BDF0-4559-8995-5614B506A408Q40646076-B8FDA927-1EB5-4431-B8A7-C2F5AECBBBBAQ41280277-A762DF59-6D32-42B3-A114-08C668ED938CQ41343761-2B186284-CF53-402E-9A2B-FC85FE8D0886Q41346357-D89A44E0-D3E5-4F5F-854C-AC492E56677BQ42351657-9C458EEF-1D20-45D8-8E34-528F5303ADB5Q42376369-E1598847-D62D-479C-B31D-53D3C2122A48Q43235785-E06991B7-9366-491D-A026-93C4F0D82F97Q43434762-76323EF5-EADD-4A67-8F89-0891A6B1AEC9Q47200008-4E59885A-523A-45A0-A4EB-6EEB043CC3D0Q47300891-4611741C-A373-4E01-BAF0-6FBF34D57FBDQ48293480-C79FBED7-E27F-4228-8CAF-0D02F4972329Q48907560-60CD2B5C-6E66-4E1C-B3BA-A3B53A1C2C3DQ53838377-76047E04-FFA4-49E2-8F75-EEA074AD78D0Q53838379-3F3F4B44-A6BF-436C-87FC-F3DADC740AAAQ55098659-BF6E5B37-0CF1-48DC-B3C7-3AB4C7B2865DQ55381654-BC28A33E-3E48-45D5-BA30-6E03AC1A3C0BQ58762210-938245F1-8F71-4720-91E6-4D004109C91C
P2860
Perspectives in the treatment of pancreatic adenocarcinoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Perspectives in the treatment of pancreatic adenocarcinoma
@ast
Perspectives in the treatment of pancreatic adenocarcinoma
@en
Perspectives in the treatment of pancreatic adenocarcinoma
@nl
type
label
Perspectives in the treatment of pancreatic adenocarcinoma
@ast
Perspectives in the treatment of pancreatic adenocarcinoma
@en
Perspectives in the treatment of pancreatic adenocarcinoma
@nl
prefLabel
Perspectives in the treatment of pancreatic adenocarcinoma
@ast
Perspectives in the treatment of pancreatic adenocarcinoma
@en
Perspectives in the treatment of pancreatic adenocarcinoma
@nl
P2860
P3181
P356
P1476
Perspectives in the treatment of pancreatic adenocarcinoma
@en
P2093
Victoria Juarez
P2860
P304
P3181
P356
10.3748/WJG.V21.I31.9297
P407
P577
2015-08-21T00:00:00Z